撥康視雲-B(02592.HK)最終發售價10.10港元 預期7月3日開始買賣
格隆匯7月2日丨撥康視雲-B(02592.HK)公告,公司最終發售價10.10港元,所得款項淨額522.21百萬港元。其中香港公開發售認購水平達78.78倍,國際發售認購水平達0.89倍。
由於國際發售認購不足且香港公開發售獲超額認購,因此已應用招股章程「全球發售的架構-香港公開發售-重新分配」一節所披露的重新分配程序。
經重新分配後,香港公開發售下的發售股份最終數目已調整至12,115,500股股份,佔全球發售下可供認購的發售股份總數約20%。
假設全球發售於2025年7月3日上午八時正或之前成爲無條件,則預期股份將於2025年7月3日上午九時正在聯交所開始買賣。股份將以每手500股股份爲買賣單位,股份的股份代號將爲2592。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.